<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>69</patient-age><report-id>PHHY2013JP006088</report-id><gender>female</gender><reactions><reaction>Renal acidosis tubular</reaction><reaction>Hypokalaemia</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>ZOMETA</drug-name><manufacturer/><ingredients/></drug></drugs><patient-age>69</patient-age><outcomes/><country>Japan</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149684_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152627</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2013JP006088</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-21</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-21</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2013JP006088</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportergivename>Hiroyuki</reportergivename>
			<reporterfamilyname>Takenaka</reporterfamilyname>
			<reporterorganization>Hirakata Kohsai Hospital</reporterorganization>
			<reportercity>Osaka Prefecture</reportercity>
			<reportercountry>JP</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
			<literaturereference>Takenaka H. et al</literaturereference>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>69</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex code="2">Female</patientsex>
			<reaction>
				<primarysourcereaction>Renal acidosis tubular</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Renal acidosis tubular</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Renal tubular acidosis</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Hypokalaemia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hypokalaemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hypokalaemia</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ZOMETA</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugauthorizationnumb>21-223</drugauthorizationnumb>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosageform normalized="solution for infusion">Solution For Infusion</drugdosageform>
				<drugadministrationroute code="041">Intravenous drip</drugadministrationroute>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypokalaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypokalaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal tubular acidosis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal tubular acidosis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2013JP006088, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>literature report received from an author on 21 Jan 2013. This case refers to a 69-year old female patient. On an unknown date, the patient received <Semaphore x="1385161" class="Medicine" value="Zometa" score="0.49" ID="242959">Zometa </Semaphore>(zoledronate), solution for <Semaphore x="2056709" class="Procedure" value="Infusion Procedure" score="1.00" ID="C15388">infusion </Semaphore>for an unknown indication at an unknown dose. On an unknown date, the patient had <Semaphore x="2039588" class="Disease or Finding" value="Hypokalemia" score="1.00" ID="C37974">hypokalemia </Semaphore>and <Semaphore x="2461411" class="Disease or Finding" value="Renal Tubular Acidosis" score="1.00" ID="C28129">renal acidosis tubular</Semaphore>. The seriousness of the events was not reported. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the events was unknown. The causality of <Semaphore x="2461411" class="Disease or Finding" value="Renal Tubular Acidosis" score="1.00" ID="C28129">renal acidosis tubular </Semaphore>was suspected while it was not reported for <Semaphore x="2039588" class="Disease or Finding" value="Hypokalemia" score="1.00" ID="C37974">hypokalemia</Semaphore>. A full <Semaphore x="1888420" class="Race" value="English" score="1.00" ID="C43853">English </Semaphore>translation of this article will follow.</narrativeincludeclinical>
				<sendercomment>MAC: Limited information precludes meaningful medical assessment of the case.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>